Printer Friendly

Antipsychotic drug doses climb over time.

Psychiatrists who prescribe antipsychotic medication for severely mentally ill individuals living in board-and-care facilities, halfway houses and other private housing arrangements tend to administer progressively larger doses of the drugs over time, according to a report in the June AMERICAN JOURNAL OF PUBLIC HEALTH.

This practice, uncovered in a study of 243 formerly hospitalized mental patients interviewed in 1973 and again in 1985, may stem primarily from a lack of community mental health services, which encourages an over-reliance on antipsychotic drugs by clinicians, asserts psychologist Steven P. Segal of the University of California, Berkeley. Segal conducted the survey with psychologist David Cohen of the University of Montreal and psychiatrist Stephen R. Marder of the University of California, Los Angeles.

One in three people contacted in 1985 by the researchers reported moderate to severe restlessness, body rigidity or spasms of the mouth and facial muscles. Antipsychotic drugs can cause these symptoms, which sometimes lead to a serious movement disorder known as tardive dyskinesia (TD). Segal's team did not assess the number of TD cases in the sample.

However, the findings challenge the notion that increasing concern over TD during the 1980s led to more conservative long-term prescriptions for antipsychotic drugs (also called neuroleptics), the scientists contend.

No other studies have examined prescription practices for mentally ill people living in "sheltered-care facilities," Segal says. Essentially a private system of residential care, the living arrangements that comprise sheltered care in the United States now house between 300,000 and 400,000 mentally ill adults. Prescriptions may be handled either by a physician working for a particular residence or by an individual's private physician or psychiatrist.

Segal's group conducted interviews in 1973 with 393 former psychiatric patients living in sheltered-care facilities located throughout California. In 1985, the investigators reinterviewed 243 surviving participants and verified the dosages of all prescribed medications. Most of those in the survey suffered from schizophrenia, a severe disruption of thought and emotion that strikes about one in 100 people.

Slightly more than three-quarters of the sample received neuroleptics in both 1973 and 1985. Of that number, nearly half experienced an increase in the prescribed neuroleptic dose over 12 years, and almost 10 percent ended up taking extreme doses, the researchers maintain.

"I was surprised at some of those doses," Segal remarks. "They're very high."

The average daily dose of antipsychotic medication increased markedly from 1973 to 1985, particularly among the 22 people receiving long-acting injections, rather than short-acting pills, at follow-up.

At the same time, Segal sees room for optimism in the finding that nearly 40 percent of persons given neuroleptics in 1973 received a lower dose 12 years later and displayed no significant drop in psychological functioning. And study participants age 56 to 65 received an average of half the neuroleptic dose prescribed for younger adults, following guidelines established for treating the older mentally ill.

Nonpsychiatric physicians took a more cautious approach to prescribing neuroleptics, perhaps because they were less familiar with the drugs, Segal notes. Patients with muscular rigidity or twitching often received additional drugs to help ease their irregular movements.

Sheltered-care facilities usually maintained links to local mental health programs that provided former patients with job training and other services, but funding cuts undermined those organizations during the 1980s, Segal contends.

He hopes to conduct a 20-year follow-up of the California sample in 1993.
COPYRIGHT 1992 Science Service, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:dosages tend to progress to larger amounts
Author:Bower, Bruce
Publication:Science News
Date:Jun 13, 1992
Previous Article:At last, neutrino results from GALLEX.
Next Article:Explanation for premature and delayed labor.

Related Articles
Rat model of tardive dyskinesia gets boost.
Antipsychotics evoke youthful concerns.
Vitamin E may ease movement disorder.
Schizophrenia: promising drug ... and infectious clues.
Schizophrenia drugs: a case for tapering.
Antipsychotics and brain changes.
Orally disintegrating olanzapine for the treatment of psychotic and behavioral disturbances associated with dementia. (Case Report).
Metabolic issues in patients with severe mental illness.
Managing the risk of tardive dyskinesia: based on an interview with William M. Glazer, MD.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters